The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Long-term follow-up of CA209-004: A phase I dose-escalation study of combined nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma.
Michael B. Atkins
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Acceleron Pharma; Aduro Biotech; Agenus; Array BioPharma; Arrowhead Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Glactone Pharma; Immunocore; Iovance Biotherapeutics; Merck; Newlink Genetics/Pharmatech; Novartis; Oncolys BioPharma; Pfizer; Surface; Werewolf Pharma; X4 Pharma
Research Funding - Bristol-Myers Squibb (Inst)
John M. Kirkwood
Consulting or Advisory Role - Amgen; Array BioPharma; Bristol-Myers Squibb; Immunocore; Merck; Novartis; Roche
Research Funding - Immunocore (Inst); Merck (Inst); Prometheus Laboratories (Inst)
Jedd D. Wolchok
Stock and Other Ownership Interests - Adaptive Biotechnologies; Ascentage Pharma; Beigene; Elucida Oncology; ImVaq; Kleo Pharmaceuticals; Linneaus; Potenza Therapeutics; Serametrix; Tizona Therapeutics, Inc.; Trieza Therapeutics
Honoraria - Amercian Association for Cancer Research; Esanex; Institut Jules Bordet Instituut
Consulting or Advisory Role - Adaptive Biotechnologies; Advaxis; Amgen; Apricity Therapeutics; Array BioPharma; Ascentage Pharma; Astellas Pharma; Bayer; Beigene; Bristol-Myers Squibb; Celgene; Chugai Pharma; F-Star Biotechnology; Genentech; Kleo Pharmaceuticals; Lilly; MedImmune; Merck; Neon Therapeutics; Ono Pharmaceutical; Polaris; Polynoma; Potenza Therapeutics; PsiOxus Therapeutics; PsiOxus Therapeutics; PureTech; Sellas Life Sciences; Serametrix; Surface Oncology; Syndax; Tizona Therapeutics, Inc.; Trieza Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); F-Star Therapeutics; Genentech/Roche (Inst); Incyte (Inst); Leap Therapeutics (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst)
Patents, Royalties, Other Intellectual Property - ALPHAVIRUS REPLICON PARTICLES EXPRESSING TRP2; Engineered Vaccinia Viruses for Cancer Immunotherapy; I am a co-inventor and receive royalties for a blood test for monitoring myeloid derived suppressor cells.; I am a co-inventor on a patent for Anti-CD40 agonist mAb fused to Monophosphoryl Lipid A (MPL) for cancer therapy; I am a co-inventor on a patent for CAR+ T cells targeting differentiation antigens as means to treat cancer; I am a co-inventor on a patent for use of oncolytic Newcastle Disease virus.; I am a co-inventor on an issued patent for DNA vaccines for treatment of cancer in companion animals.; I am co-inventor and receive royalties for a patent for immune modulating antibodies.
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Bristol-Myers Squibb; Celegene Therapeutics; Chugai Pharma; Janssen; MedImmune; Novartis; Ono Pharmaceutical; Potenza Pharmaceuticals; Roche; Tizona Therapeutics, Inc.
Margaret K. Callahan
Employment - Bristol-Myers Squibb (I); Bristol-Myers Squibb (I); Celgene (I); Kleo Pharmaceuticals (I)
Consulting or Advisory Role - AstraZeneca; Merck; Moderna Therapeutics
Research Funding - Bristol-Myers Squibb (Inst)
Other Relationship - Clinical Care Options; Potomac Center for Medical Education
Harriet M. Kluger
Consulting or Advisory Role - Biodesix; Celldex; Corvus Pharmaceuticals; Genentech/Roche; Immunocore; Iovance Biotherapeutics; Merck; Nektar; Pfizer
Research Funding - Apexigen (Inst); Bristol-Myers Squibb (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Apexigen
Michael A. Postow
Honoraria - Bristol-Myers Squibb; Merck
Consulting or Advisory Role - Aduro Biotech; Array BioPharma; Bristol-Myers Squibb; Incyte; Merck; Newlink Genetics; Novartis
Research Funding - Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Infinity Pharmaceuticals (Inst); Merck (Inst); Novartis (Inst); Rgenix (Inst)
Neil Howard Segal
Consulting or Advisory Role - Aduro Biotech; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; CStone Pharmaceuticals; EMD Serono; Gritstone Oncology; Horizon Pharma; IFM Therapeutics; Imugene; Kyn therapeutics; Merck; Pfizer; Pieris Pharmaceuticals; PsiOxus Therapeutics; PureTech; Roche/Genentech; Synlogic; TRM Oncology
Research Funding - Bristol-Myers Squibb; Incyte; MedImmune; Merck; Pfizer; Roche/Genentech
Alexander M. Lesokhin
Honoraria - Bristol-Myers Squibb; Celgene; Celldex; Genmab; Takeda
Consulting or Advisory Role - Aduro Biotech; Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb (Inst); Genentech (Inst); Janssen Oncology (Inst); Sanofi (Inst); Trillium Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Serametrix, Inc
Agnes Balogh
Employment - Brystol-Myers-Squibb
Sandra Re
Employment - Brystol-Myers-Squibb
Mario Sznol
Stock and Other Ownership Interests - Actym Therapeutics; Adaptive Biotechnologies; Amphivena; Intensity Therapeutics; Torque
Consulting or Advisory Role - Abbvie; Adaptimmune; Allakos; Almac Diagnostics; Array BioPharma; AstraZeneca/MedImmune; Biodesix; Bristol-Myers Squibb; Celldex; Genentech/Roche; Genmab; Gritstone Oncology; Hinge; immunocore; Incyte; Innate Pharma; Inovio Pharmaceuticals; Kyowa Hakko Kirin; Lilly; Merck Sharp & Dohme; Modulate; Molecular Partners; Nektar; Newlink Genetics; Novartis; Omniox; Pieris Pharmaceuticals; Pierre Fabre; Seattle Genetics; Symphogen; Theravance; Torque
Other Relationship - AcademicCME; Clinical Care Options; DAVAOncology; Haymarket Media; Imedex; Physician Education Resource; Prime Oncology; Research to Practice; TRM Oncology; Vindico